Nature Communications (Nov 2021)
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
- Hakimeh Ebrahimi-Nik,
- Marmar Moussa,
- Ryan P. Englander,
- Summit Singhaviranon,
- Justine Michaux,
- HuiSong Pak,
- Hiroko Miyadera,
- William L. Corwin,
- Grant L. J. Keller,
- Adam T. Hagymasi,
- Tatiana V. Shcheglova,
- George Coukos,
- Brian M. Baker,
- Ion I. Mandoiu,
- Michal Bassani-Sternberg,
- Pramod K. Srivastava
Affiliations
- Hakimeh Ebrahimi-Nik
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Marmar Moussa
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Ryan P. Englander
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Summit Singhaviranon
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Justine Michaux
- Ludwig Institute for Cancer Research, University of Lausanne
- HuiSong Pak
- Ludwig Institute for Cancer Research, University of Lausanne
- Hiroko Miyadera
- Department of Medical Genetics, Faculty of Medicine, University of Tsukuba
- William L. Corwin
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Grant L. J. Keller
- Department of Chemistry and Biochemistry and Harper Cancer Research Institute, University of Notre Dame
- Adam T. Hagymasi
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- Tatiana V. Shcheglova
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- George Coukos
- Ludwig Institute for Cancer Research, University of Lausanne
- Brian M. Baker
- Department of Chemistry and Biochemistry and Harper Cancer Research Institute, University of Notre Dame
- Ion I. Mandoiu
- Department of Computer Sciences, University of Connecticut School of Engineering
- Michal Bassani-Sternberg
- Ludwig Institute for Cancer Research, University of Lausanne
- Pramod K. Srivastava
- Department of Immunology and Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-26646-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.
